Research Article

Metabolomics-Based Pharmacodynamic Analysis of Zhuang Yao Shuang Lu Tong Nao Granules in a Rat Model of Ischemic Cerebral Infarction

Yang Zhai,1,2 Yangling Chen,1 Yihui Luo,2 Xiaoping Mei,2 Lin Wu,3 Xueni Mo,3 Min Zou,2 Mingzhao Zhou,2 Yangling Wu,2 Guangshan Zheng,2 Peng Yang,2 Qingyu He,4 and Rui Chen4

1Graduate School, Guangxi University of Chinese Medicine, China
2Guangxi International Zhuang Medicine Hospital, China
3Department of Neurology, Guangxi University of Chinese Medicine, China
4Faculty of Chinese Medicine Science, Guangxi University of Chinese Medicine, China

Correspondence should be addressed to Rui Chen; chenr@gxtcmu.edu.cn

Received 7 April 2022; Revised 30 May 2022; Accepted 4 June 2022; Published 4 July 2022

Academic Editor: Monica C. Botelho

Copyright © 2022 Yang Zhai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study used a metabolomic approach to reveal changes in the levels of metabolic biomarkers and related metabolic pathways before and after Zhuang Yao Shuang Lu Tong Nao granule (YHT) treatment in rats with cerebral ischemia. The neurological deficit scores were significantly higher in the MCAO_R group than in the NC group, indicating that the mice had significantly impaired motor functions. The YHT group had significantly lower scores than the MCAO_R group, suggesting that YHT significantly improved motor function in rats. TTC staining of the brain tissue revealed that YHT significantly reduced the area of cerebral infarction in the treated rats. The MCAO_R group was better separated from the NC group, sham, and YHT groups via metabolomic PCA. Moreover, there were significant differences in the differential metabolites between the MACO_R and YHT groups. Eighteen common differential metabolites were detected between the MACO_R and NC groups, MACO_R and sham groups, and MACO_R and YHT groups, indicating that YHT significantly increased the levels of various metabolites in the serum of cerebral ischemic stroke (CIS) rats. Moreover, a total of 23 metabolic pathways were obtained. We identified 11 metabolic pathways with the most significant effects in the bubble plots. In conclusion, from a systems biology perspective, this metabolomics-based study showed that YHT could be used to treat ischemic stroke by modulating changes in endogenous metabolites.

1. Introduction

Cerebral ischemic stroke (CIS), also known as acute ischemic cerebrovascular disease, is localized ischemic necrosis of the brain tissue caused by an inadequate blood supply. It is the second leading cause of death worldwide, with a very high mortality rate [1–3]. It is also the leading cause of disability globally, with half of the surviving patients being left with chronic disabilities [4, 5]. The pathophysiology of CIS involves the initial development of irreversibly damaged necrotic tissue cores within the vascular bed, followed by damage around the infarcted area [6–8]. Traditional Chinese medicine (TCM) has a long history of preventing and treating ischemic stroke and promoting the recovery of neurological function after stroke [9]. It is believed that the development of ischemic cerebrovascular disease belongs to the scope of TCM, with the disease showing evidence of a deficiency of the root and the symptoms [10–12].

Zhuang Yao Shuang Lu Tong Nao granule (YHT) is a compound preparation with local characteristics developed by Guangxi International Zhuang Medical Hospital based on the Zhuangtong Drink, which is commonly used in clinical practice. It is mainly composed of four Guangxi characteristic Zhuang medicinal herbs, including Euonymus 3.
Polygala fallax H msl [18]; and Polygala fallax H msl has anti-inflammatory, anti-oxidant, and neuroprotective effects [19]. In recent years, YHT has been widely used in clinical ischemic stroke for its efficacy in tonifying qi and activating and promoting blood circulation [20–22]. Many studies have been conducted on the use of herbs for the treatment of diseases. Euonymus laxiflorus Champ has been found to exhibit several potent biological activities, including anti-NO, enzyme inhibition, and hypoglycemic and anti-diabetic effects. Morphin treatment for five days may protect the heart from ischemia-reperfusion (IR) injury [23]. However, no studies have been conducted on the strong medicine Shuanglu Tong-gue granules.

As a newly developed technology, metabolomics studies the dynamic processes involving metabolites in biological systems after stimulation or disturbance, revealing the metabolic pathways governing biological systems [24–27]. Metabolomics has been successfully used for the diagnosis and classification of early tumors [28], Alzheimer’s disease [29], cardiovascular disease [30], cancer [31], and diabetes [32]. Traditional Chinese medicine emphasizes the overall balance of yin and yang in the course of treatment for a disease, which is not limited to a certain body part or organ [33]. Therefore, metabolomics is based on systems thinking, and a holistic view focuses on the metabolic profile of endogenous small molecules and the tracking of changes in metabolites to define the state of the body. It is currently one of the most effective ways to evaluate the mechanism of action of Chinese medicine compounds to reflect the functional state of an organism objectively.

At present, there is no research report on the pharmacodynamic effects of ischemic stroke using ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry from the perspective of its endogenous molecular metabolism. From the change law of endogenous blood metabolites in rats, we used ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-MS/MS), principal component analysis (PCA), and partial least squares discriminant analysis (PLS-DA) to reveal the mechanism underlying endogenous molecular metabolism and explain the mode of action of the corresponding active compounds of YHT. Furthermore, we also determined the theoretical significance behind these findings and their broad clinical application prospects.

2. Materials and Methods

2.1. Materials. Male SD rats (SPF class, 200–230 g) were obtained from Vital River Laboratory Animal Technology Co. Ltd. (Beijing, China; license number SCXK (Hubei) 2017-0012). All rats were housed in a standard environment (humidity, 60 ± 5%, temperature 25 ± 2 °C). Animal experiments were conducted at the Animal Experimentation Center, in accordance with the National Laboratory Animal Welfare Guidelines.

2.2. Preparation of YHT. YHT included the following components: 15 g Cinnamomum cassiaPt sl, 15 g Autacuylod slanca (Thunb.) DC, 15 g Ctau a gus cun aua Sieb. Et Zucc., 15 g Ciutus tuiculaua Blanco, 10 g Rhizoma Pinelliae, 15 g Potia cocos (Schw.) Wolf, 10 g Panax notoginseng (Burk.) F. H. Chen, 20 g Euonymus 5 otuun (Turcz.) Hand.–Mazz., 15 g Zingiber officinale Roscoe, 5 g Glycyrrhizae, and 20 g Polygala aureocauda Dunn. The mixture was immersed in distilled water for 1 h. Reflux extraction was then performed thrice for 1.5 h each time. Afterward, the extract was subjected to water decoction thrice, filtered, and concentrated until it had a syrup-like viscosity and dried in a vacuum drying box at 70 °C before obtaining the dry extract.

Quality standards of drug raw materials (medicinal materials) are the following: Cinnamomum cassiaPt sl, Autacuylod slanca (Thunb.) DC, Ctau a gus cun aua Sieb. Et Zucc., Ciutus tuiculaua Blanco, Rhizoma Pinelliae, Potia

| Table 1: Neurological function scoring criteria. |
|-----------------------------------------------|
| Performance | Rating/score |
| Longa rating | |
| No defects | 0 |
| Difficulty in full extension of the contralateral forelimb | 1 |
| Rotate to opposite side | 2 |
| Drop to the opposite side | 3 |
| Inability to walk spontaneously | 4 |
| Bederson rating | |
| No defects | 0 |
| It is difficult to fully extend the contralateral forelimb when lifting the tail | 1 |
| Rotate to opposite side | 2 |
| Reduced contralateral push resistance (and forelimb flexion) without circling | 3 |
| Reduced contralateral push resistance (and forelimb flexion) | 4 |

| Table 2: The gradient of mobile phase. |
|--------------------------------------|
| Time (min) | Flow rate (mL/min) | A (%) | B (%) |
| 0.00 | 0.65 | 5 | 95 |
| 0.5 | 0.65 | 5 | 95 |
| 9.5 | 0.65 | 35 | 65 |
| 11.50 | 0.65 | 60 | 40 |
| 13.50 | 0.65 | 60 | 40 |
| 13.60 | 0.65 | 5 | 95 |
| 16.00 | 0.65 | 5 | 95 |
cocos (Schw.) Wolf, Panax notoginseng (Burk.) F. H. Chen, Euonymus 5 otuun (Turcz.) Hand.—Mazz., Zingiber officinale Roscoe, Glycyrrhiza, and Polygala aureocauda Dunn met the requirements of the Pharmacopoeia of the People’s Republic of China (Volume I, 2020 Edition). The content of corresponding drugs was made sure not to be lower than the specified standards, which were identified by the Department of Traditional Chinese Medicine of the Guangxi University of Traditional Chinese Medicine.

### 2.3. Construction of Animal Models
A rat model of middle cerebral artery occlusion (MCAO) was prepared according to the modified Longa-suture-occluded method. All surgical tools were sterilized under high pressure. After 24 h of fasting, the rats were anesthetized with 10% chloral hydrate (10 mL/kg, i.p.) and fixed on a table. Using a scalpel, the neck skin of the rats was longitudinally cut along the middle of the neck, and the subcutaneous glands and tissues were gradually separated to expose the bilateral common carotid artery (CCA) and external carotid artery (ECA). After ligating the distal end of the ECA and the proximal end of the CCA and clamping the distal end of the ICA with an artery, a small incision was performed in the common carotid artery and the external carotid artery bifurcation. A fishing line (diameter: 0.26 mm) with a rounded tip was inserted into the ICA to the region approximately 2 cm above the bifurcation until resistance was felt. Finally, the ICA was moderately ligated with a suture line, and the neck skin was sutured and sterilized. After 2 h, the plug line was gently pulled out and reperfusion was performed, and the rats were placed in a metabolic cage. The rats in the sham operation group only had their left cerebral artery exposed and did not undergo insertion. During and after the operation, the temperature was maintained at approximately 25-30°C.

### 2.4. Experimental Grouping and Drug Treatment
After the adaptation period, the rats were randomly divided into four groups \((n = 4 \text{ each group})\). The control group (NC) received normal feeding and had free access to drinking water, gastric perfusion, other volumes of normal saline twice a day (morning/afternoon), and 3 d death after reperfusion. In the model group (MCAO_R), after animal model establishment, the rats received normal feeding and had free access to drinking water, gastric perfusion, other volumes of normal saline twice a day (morning/afternoon), and 3 d death after reperfusion. Rats in the sham operation group (sham) underwent the same procedure as the model group but were not ligated to the artery. After waking up, the rats in this group received normal feeding and had free access to drinking water, gastric perfusion, and other volumes of normal saline twice a day (morning/afternoon) and 3 d death after reperfusion. Finally, in the treatment group (YHT), after establishing the rat MCAO model, the rats were made sober 1 h after anesthesia and were administered intragastrically with Zhuang Yao Shuanglu Tongnao granule water decocction twice a day (morning/afternoon, 1.4 mL/100 g each time) and 3 days after reperfusion. All the rats were administered intragastrically daily for 3 days.

### 2.5. Neurological Function Score
After 2 h of ischemia, the neurological function of the rats was scored using the Longa and Bederson scoring system. This system involves scoring from 0 to 4, with higher scores indicating more severe neurological deficits than lower scores. The specific evaluation criteria for this system are listed in Table 1.

### 2.6. TTC Staining of Brain Tissue
After the cerebellum and olfactory bulbs were removed, the brains of the rats were placed in a refrigerator at \(-20\)°C for 5 min. The brains were then cut into four pieces along the optic chiasm and 2 mm along the optic nerve. The brain slices were stained in 2% TTC solution and placed in a water bath at 37°C. After 20 min, the brain slices were removed, washed in normal saline three times, and fixed in a 10% formaldehyde solution for 24 h for imaging.

### 2.7. Preparation of Serum Samples
After 24 h of reperfusion, 2 mL of the orbital blood was collected and placed in an EP tube. After incubation for 30 min, the supernatant was centrifuged at 4000 rpm, 4°C for 10 min. The supernatant was then extracted using a pipette gun and transferred to an EP tube. After labeling, the supernatant was placed in a
Figure 2: Continued.
refrigerator at $-80^\circ$C. Finally, the metabolomic parameters of the collected serum were analyzed.

2.8. UPLC-MS/MS Analysis. All cryopreserved sera require additional treatment before UPLC-MS/MS analysis. First, serum samples were removed from a $-80^\circ$C refrigerator and were thawed slowly on ice. Next, 100 $\mu$L aliquots were placed in 1.5 mL centrifuge tubes, 300 $\mu$L of methanol was added to the serum aliquots, and the mixture was vortexed for 30 s. The solutions were then incubated for 1 h at $-40^\circ$C. The solutions were vortexed again for 30 s and then incubated for 30 min at 4°C. Then, the solutions were centrifuged at 4°C, 12000 rpm for 15 min, the supernatants were collected in centrifuge tubes, and the tubes were incubated for 1 h at $-40^\circ$C. Finally, the collected supernatants were centrifuged again at 4°C, 12000 rpm for 15 min, and 200 $\mu$L of the clear supernatant was collected. This, including 5 $\mu$L of an internal standard (140 $\mu$g/mL dichlorophenylalanine), was subjected to UPLC/MS-MS analysis.

2.9. Chromatographic Separation Conditions. Column temperature is 40°C, flow rate is 0.65 mL/min, mobile phase A is water with 10 mM ammonium formate, mobile phase B is acetonitrile with 10 mM ammonium formate, injection volume is 3 $\mu$L, and automatic injector temperature is 4°C (Table 2). The mass spectrometry conditions are as follows: ESI+; heater temperature is 300°C; sheath gas flow rate is 45 arb; aux gas flow rate is 15 arb; sweep gas flow rate is 1 arb; spray voltage is 3.0 kV; capillary temperature is 350°C; S-Lens RF level is 30%.

2.10. Data Processing and Analysis. Feature extraction was performed, and the data obtained were preprocessed using Compound Discoverer software (Thermo) and then normalized and edited into a two-dimensional data matrix using Excel 2010 software, including the retention time (RT), compound molecular weight (compMW), observations (samples), and peak intensity.

To reveal the differences in metabolites among the different groups, the data were input into SIMCA software (v14.1, Sartorius Stedim data analytics AB, Umea, Sweden) and subjected to a series of multivariate pattern recognition analyses, including PCA, PLS-DA, and orthogonal partial least squares discriminant analysis (OPLS-DA). At the same time, different metabolites were screened based on the principle regarding the $P$ value of Student’s $t$-test ($P \leq 0.05$) and the

![Figure 2: Principal component analysis and partial least squares discriminant analysis of the components of mouse serum: (a) principal component analysis for each group of rats; (b) principal component analysis between the NC and MCAO_R groups; (c) principal component analysis between the sham and MCAO_R groups; (d) principal component analysis between the MCAO_R and YHT groups; (e) partial least squares discriminant analysis between the NC and MCAO_R groups; (f) partial least squares discriminant analysis between the sham and MCAO_R groups; (g) partial least squares discriminant analysis between the MCAO_R and YHT groups.](image-url)
Figure 3: Continued.
Variable Importance in the Projection (VIP ≥ 1), the first main component of the OPLS-DA model. The results were visualized using volcano plots. In addition, hierarchical clustering (HCA) and correlation analysis of the metabolites were used to reveal the relationship between samples and metabolites. Finally, the biological significance of the metabolites was explained through a functional analysis of the metabolic pathways involved.

3. Results

3.1. Effects of YHT on Neurological Function and Cerebral Infarction in Mouse Model. Neurological function scores were obtained for each group of mice (Figure 1(a)). It was found that the scores in the MCAO_R group were significantly higher ($P < 0.05$) than those in the NC group, indicating that the mice had increased walking difficulty toward the contralateral side, and the model was successfully constructed. Moreover, the neurological function scores were significantly lower in the YHT group than in the MCAO_R group ($P < 0.05$). We then observed the brain tissue conditions of the mice using TTC staining (Figure 1(b)). There was no obvious infarction in the brain tissues of rats from the NC and sham groups, while those in the MCAO_R group had severe brain tissue infarction. The infarcts in the YHT group were significantly reduced compared with those in the MCAO_R group. These results indicate that YHT can relieve the symptoms of middle cerebral artery occlusion by reducing cerebral infarction.

3.2. Principal Component Analysis and Partial Least Squares Discriminant Analysis of the Metabolites Present in the Rat Serum. PCA was performed on the sera of rats to observe the overall distribution trends of metabolites in each group and the changes in these trends after YHT treatment. The results showed that the MCAO_R group was distributed below the circle and was separated from the other groups of mice, while the NC and sham groups had a crossover distribution, indicating that the metabolites in the two groups did not differ significantly. Since no ischemia experiments were performed in these groups, the effect of traumatic manipulation on cerebral ischemia metabolism was not significant. The YHT group was well separated from the MCAO_R group, indicating that YHT could relatively improve cerebral ischemia (Figure 2(a)). To observe the effect of YHT treatment on serum metabolites more clearly, a discriminant model was developed in this study between the MCAO_R and NC groups, the MCAO_R and sham groups, and the MCAO_R and YHT groups. The score charts of the MCAO_R and NC groups are shown in Figure 2(e). The MCAO_R and NC groups were significantly located on both sides, indicating significant differences in the metabolic components between the two groups. The model interpretation capability parameter ($R^2_Y$) was 0.99, and the
other prediction capability parameter ($Q^2$) was 0.93, indicating that the model has a good ability to distinguish and predict. According to the permutation test, all $R^2$ values were higher than the $Q^2$ values, and their values were close to 1. This indicates an absence of overfitting in the model, so it could be used to screen the differential markers. For example, the $R^2$ and $Q^2$ values were 0.99 and 0.93, respectively, when comparing the MACO_R group with the sham group (Figure 2(f)); the $R^2$ values were higher than the $Q^2$ values according to the permutation test. Similarly, between the MCAO_R group and the YHT group, the $R^2$ and $Q^2$ values were 1.0 and 0.93, respectively (Figure 2(g)). The permutation test results also showed that the model was similar to the above model, so it can also be used to screen for differential markers.

### Table 3: Differential metabolites in serum samples.

| Number | Metabolites           | Molecular formula | RT (min) | $P$ value | MACO_R/NC | MACO_R/sham | MACO_R/YHT | MACO_R/NC | MACO_R/sham | MACO_R/YHT | Fold change |
|--------|-----------------------|-------------------|----------|-----------|-----------|-------------|-------------|-----------|-------------|-------------|-------------|
| 1      | Creatine              | C$_4$H$_9$N$_3$O$_2$ | 10.795   | <0.001    |           | <0.001      | 0.043       |           | 1.379       | 1.465       | 0.939       |
| 2      | L-Citrulline          | C$_4$H$_7$N$_2$O$_3$ | 11.832   | 0.001     |           | <0.001      | 0.005       | 0.705     | 0.742       | 0.717       |             |
| 3      | L-Isoluecine          | C$_4$H$_7$N$_2$O$_3$ | 8.744    | 0.008     | 0.012     | 0.006       | 1.257       | 1.265     | 1.268       | 0.668       |             |
| 4      | SM(d18/1/16/0)        | C$_5$H$_9$N$_2$O$_6$ | 5.104    | 0.004     | <0.001    | 0.002       | 1.238       |           | 1.268       | 0.723       |             |
| 5      | Trigonelline          | C$_4$H$_7$N$_2$O$_3$ | 9.499    | 0.024     | 0.019     | <0.001      | 0.265       | 0.221     | 0.179       |             |             |
| 6      | L-Glutamic acid       | C$_5$H$_8$N$_4$O$_4$ | 12.589   | <0.001    | <0.001    | 0.013       | 0.410       | 0.460     | 0.638       |             |             |
| 7      | 4-Guanidinoobutyric    | C$_5$H$_9$N$_2$O$_2$ | 10.878   | 0.037     | 0.018     | 0.006       | 0.369       | 0.307     | 0.726       |             |             |
| 8      | Guanidineacetate       | C$_6$H$_7$N$_2$O$_2$ | 10.949   | 0.012     | 0.001     | 0.001       | 0.445       | 0.384     | 0.224       |             |             |
| 9      | Pyroglutamic acid      | C$_5$H$_8$N$_2$O$_3$ | 12.540   | <0.001    | 0.001     | 0.026       | 0.425       | 0.477     | 0.670       |             |             |
| 10     | Prolylleucine          | C$_5$H$_7$N$_2$O$_3$ | 11.366   | 0.026     | 0.001     | 0.045       | 1.499       | 2.079     | 1.770       |             |             |
| 11     | L-Aspartic acid        | C$_5$H$_7$N$_2$O$_2$ | 12.746   | <0.001    | 0.023     | 0.010       | 0.305       | 0.250     | 0.352       |             |             |
| 12     | Eicosapentaenoic acid  | C$_5$H$_5$N$_2$O$_2$ | 2.468    | 0.005     | 0.015     | 0.039       | 0.148       | 0.165     | 4.080       |             |             |
| 13     | Sphingosine            | C$_5$H$_7$N$_2$O$_2$ | 5.079    | 0.005     | <0.001    | 0.002       | 0.238       | 0.222     | 2.216       |             |             |
| 14     | Argininosuccinic acid  | C$_6$H$_8$N$_4$O$_6$ | 13.513   | 0.017     | 0.004     | 0.023       | 0.535       | 0.555     | 0.432       |             |             |
| 15     | Arecoline              | C$_6$H$_7$N$_2$O$_2$ | 10.695   | 0.040     | 0.028     | 0.002       | 0.180       | 0.156     | 2.200       |             |             |
| 16     | trans-3-Indoleacrylic acid | C$_6$H$_7$N$_2$O$_2$ | 2.538    | 0.004     | 0.003     | 0.043       | 0.353       | 0.311     | 3.577       |             |             |
| 17     | Paracetamol            | C$_6$H$_5$NO$_2$   | 11.158   | 0.001     | <0.001    | 0.001       | 2.013       | 1.780     | 0.151       |             |             |
| 18     | 2′-O-Methylguanosine   | C$_6$H$_13$N$_3$O$_5$ | 6.812    | 0.030     | 0.011     | 0.006       | 0.700       | 0.691     | 0.274       |             |             |

3.3. Identification of Differential Serum Metabolites. After analysis, it was confirmed that the model could be used to screen for differential markers. Differential metabolites were screened using the cardinality criterion of Student’s $t$-test ($P < 0.05$), while Variable Importance in the Projection (VIP) > 1 was the first principal component of the OPLS-DA model. We visualized the results of screening the differential metabolites using a volcano plot and then performed a hierarchical cluster analysis on the characteristics of the obtained differential metabolites. Each point in the volcano plot represents a metabolite, while the scatter color represents the final screening result. Significantly upregulated metabolites are shown in red, significantly downregulated ones are shown in blue, and nonsignificantly different ones are shown in gray. The MACO_R group was analyzed separately from the other groups (NC, sham, and YHT) for differential metabolite levels. In the analysis of the MACO_R group versus the NC group (Figure 3(a)), the changes in the differential metabolites were opposite. Similarly, in the comparative analysis between the sham group (Figure 3(b)) and the YHT group (Figure 3(c)), an opposite trend was found in the changes in differential metabolites compared to the MACO_R group. Eighteen common differential metabolites were detected between the MACO_R and NC groups, the MACO_R and sham groups, and the MACO_R and YHT groups (Table 3). These results suggest that YHT can improve cerebral ischemia in rats by regulating the metabolism of endogenous substances in the serum, with good therapeutic effects.

3.4. Metabolic Pathway Analysis. Compositional analysis and screening identified the differential endogenous metabolites in rat serum. The MetaboAnalyst 4.0 and KEGG databases were used to analyze the relevant metabolic pathways of these metabolites. A total of 23 metabolic pathways were
identified (Table 4), including the metabolism of arginine and proline; biosynthesis of arginine; metabolism of glutathione; metabolism of histidine; metabolism of sphingomyelin; biosynthesis of aminoacyl tRNA; metabolism of alanine, aspartate, and glutamate; metabolism of nitrogen; metabolism of D-glutamine and D-glutamate; biosynthesis of valine, leucine, and isoleucine; metabolism of phenylalanine; metabolism of butyric acid; metabolism of nicotinic acid and nicotinamide; biosynthesis of pantothenic acid and CoA; metabolism of porphyrins and chlorophyll; metabolism of acetaldehyde and dicarboxylic acids; biosynthesis of unsaturated fatty acids; metabolism of pyrimidines; and degradation of valine, leucine, and isoleucine. Using bubble plots, we then identified 11 metabolic pathways with the most significant effects (Figure 4): arginine and proline metabolism; arginine biosynthesis; glutathione metabolism; histidine metabolism; sphingolipid metabolism; aminoacyl-tRNA biosynthesis; alanine, aspartate, and glutamate metabolism; glycine, serine, and threonine metabolism; alanine, aspartate, and glutamate metabolism; phenylalanine, tyrosine, and tryptophan biosynthesis; D-glutamine and D-glutamate metabolism; and phenylalanine metabolism.

### Table 4: Metabolic pathway analysis.

| Pathway                                      | Raw P  | -ln(P) | FDR     | Impact  |
|----------------------------------------------|--------|--------|---------|---------|
| Arginine and proline metabolism              | <0.001 | 9.258  | 0.006   | 0.122   |
| Arginine biosynthesis                        | <0.001 | 8.846  | 0.006   | 0.462   |
| Glutathione metabolism                       | 0.002  | 6.037  | 0.067   | 0.054   |
| Histidine metabolism                         | 0.004  | 5.515  | 0.085   | 0.000   |
| Sphingolipid metabolism                      | 0.009  | 4.723  | 0.149   | 0.069   |
| Aminoacyl-tRNA biosynthesis                  | 0.017  | 4.084  | 0.236   | <0.001  |
| Alanine, aspartate, and glutamate metabolism | 0.020  | 3.922  | 0.238   | 0.442   |
| Glycine, serine, and threonine metabolism    | 0.033  | 3.405  | 0.349   | 0.092   |
| Beta-alanine metabolism                      | 0.071  | 2.642  | 0.665   | 0.056   |
| Phenylalanine, tyrosine, and tryptophan biosynthesis | 0.082  | 2.498  | 0.691   | 0.500   |
| Nitrogen metabolism                          | 0.121  | 2.113  | 0.846   | <0.001  |
| D-Glutamine and D-glutamate metabolism       | 0.158  | 2.113  | 0.846   | 0.500   |
| Valine, leucine, and isoleucine biosynthesis | 0.158  | 1.846  | 1.000   | <0.001  |
| Phenylalanine metabolism                     | 0.228  | 1.481  | 1.000   | 0.357   |
| Butanoate metabolism                         | 0.276  | 1.287  | 1.000   | <0.001  |
| Nicotinate and nicotinamide metabolism       | 0.276  | 1.287  | 1.000   | <0.001  |
| Pantothenate and CoA biosynthesis            | 0.336  | 1.090  | 1.000   | <0.001  |
| Porphyrin and chlorophyll metabolism         | 0.478  | 0.739  | 1.000   | <0.001  |
| Glyoxylate and dicarboxylate metabolism      | 0.500  | 0.693  | 1.000   | <0.001  |
| Biosynthesis of unsaturated fatty acids      | 0.542  | 0.613  | 1.000   | <0.001  |
| Pyrimidine metabolism                        | 0.571  | 0.560  | 1.000   | 0.005   |
| Valine, leucine, and isoleucine degradation  | 0.581  | 0.544  | 1.000   | <0.001  |

## 4. Discussion

CIS is the second leading cause of death [34]. It causes neurological impairments leading to various complications, including Parkinson’s disease, chorea, vision loss, and memory loss, and has a mortality rate of up to 30% [35]. Its pathogenesis is unclear, and the available drugs for this disease are not ideal. Therefore, finding effective ways to treat and prevent stroke is essential. Many clinical and experimental studies have demonstrated that YHT has multiple biological activities, such as vasodilation, antioxidant activity, reducing blood viscosity, improving microcirculation, and promoting the proliferation of endogenous neural stem cells and neural regeneration after ischemic stroke [20].

Many studies have shown that the MCAO model is consistent with human stroke pathogenesis and has the advantages of good reproducibility and stability, thus providing a powerful tool for ischemic encephalopathy research and drug screening [34]. This study revealed changes in the levels of metabolic biomarkers and related metabolic pathways before and after YHT treatment in cerebral ischemic rats. The results revealed that YHT treatment significantly reduced neurological function scores, indicating that it restored CIS-induced motor impairment, improved brain damage, and reduced the area of cerebral infarction in a rat model of ischemic cerebral infarction. Moreover, metabolomic PCA revealed that the YHT group was well-separated from the MCAO_R group. Analysis of differential metabolites in mouse serum also revealed that YHT significantly improved various metabolites in the serum of CIS rats.

Eleven metabolic pathways with the most significant effects were identified using bubble plots. In the amino acid
metabolism pathway, glutamine produces glutamic acid and ammonia through glutaminase. It then enters the TCA cycle through glutamic acid dehydrogenase, aspartate aminotransferase, and alanine aminotransferase to produce α-ketoglutaric acid. Alternatively, it can be completely oxidized to CO₂ or partially oxidized to produce alanine, aspartate, or lactic acid. L292 cells mainly convert glutamine to aspartic and glutamic acids. As a neurotransmitter, when the amount of glutamate in the intercellular space increases, the concentration of excitatory amino acids increases. This, in turn, activates NMDA receptors, opens calcium channels, stimulates a large number of free radicals, activates postsynaptic glutamate receptors, activates enzymes, and triggers signaling cascade reactions. Glutamate and aspartate may also produce neurotoxins. This reaction cascade allows oxygen radicals and other messengers to activate inflammatory cytokines and enzymes to trigger an inflammatory response in activated microglia. Inflammation produces free radicals, which can lead to a vicious cycle. Arginine is an amino acid wherein proline is an alternative precursor for its synthesis. Arginine can be synthesized from citrulline through the metabolism of glutamine and proline. Arginine exerts antioxidant effects by reducing the production of superoxide anions in the body. It can also accelerate the ornithine cycle, in which carbamyl phosphate participates in urea synthesis, increases the formation of urea, and accelerates the removal of ammonia. A deficiency in arginine leads to the accumulation of carbamyl phosphate, increasing the production of whey acid. Aminoformyl phosphate reacts with ornithine to form citrulline and phosphoric acid, becomes converted to arginine, and cleaves to ornithine and urea. Ornithine can be interconverted with arginine, proline, and glutamic

**Figure 4:** Analysis of metabolic pathways.
acid and transferred to α-keto acid, glyoxylic acid, and ornithine dehydroxylase to produce butylenediamine. These products can be used as precursors to further synthesize polyamines. Ornithine and citrulline can reduce the negative nitrogen balance and improve immunity, respectively.

Lipids also have essential biological functions. Metabolic disorders can cause inflammation, nerve cell damage, degeneration, and even death, causing irreversible damage to the brain. The glycerol phospholipid pathway plays an important role in promoting blood circulation and preventing blood stasis. Phospholipids and sphingolipids are essential components of the brain lipids. Glycerolipids are the most widely distributed phospholipid components in the cell membrane, and their content is relatively high. Sphingomyelin is the main lipid in myelin. Cell membranes in the brain can quickly respond to changes in the environment, which requires the continuous regulation of membrane phospholipids and sphingolipids. When lipid metabolism is disturbed, excitatory amino acid receptors are stimulated, and calcium channels and associated phospholipases are activated. Phospholipase hydrolyzes phosphatidylcholine and phosphatidylethanolamine on the cell membrane into diglyceride, phosphatic acid, arachidonic acid, and other chemical moieties. Simultaneously, arachidonic acid activates sphingolipase to hydrolyze sphingolipids into ceramide. Ceramide induces neuronal apoptosis by inhibiting the mitochondria and releasing cytochrome. Under the action of phospholipase, arachidonic acid produces phosphatidylglycerol, phosphatidylserine, phosphatidylinositol, and phosphatidylethanolamine, all of which participate in cell membrane reconstruction. In summary, the main action of YHT is carried out through the seven metabolic pathways mentioned above, while the mechanism of activating blood circulation and resolving blood stasis may be more similar to the changes in amino acid and phospholipid metabolic pathways. This needs to be explored further in future research.

5. Conclusion

In conclusion, YHT promoted the recovery of neurological function and significantly reduced the area of brain infarction in MCAO model rats. Metabolic studies have suggested that the apparent neuroprotective mechanism of prolotherapy in a focal cerebral ischemia model is related to the changes in the levels of endogenous metabolites. However, the bioactive compounds responsible for the anti-ischemic effect of YHT need to be verified in further studies.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

All authors declare that they have no conflicts of interest.

Authors’ Contributions

Yang Zhai, Yangling Chen, Yihui Luo, and Xiaoping Mei contributed equally to this work.

Acknowledgments

This project was supported by the National Natural Science Foundation of China (81874453), Natural Science Foundation of Guangxi Province (2020JJJA140299), Innovation Project of Guangxi Graduate Education (YCBZ2021076), Guangxi TCM Self-Funded Scientific Research Project (GXZYZZ20210054, and GXZYZZ20210447), Key Research and Development Program of Guangxi Science and Technology Department (AD18281094), and Innovation and Entrepreneurship Training Program for College Students (202013643007).

References

[1] C. Zerna, G. Thomalla, B. C. V. Campbell, J.-H. Rha, and M. D. Hill, “Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke,” Lancet, vol. 392, no. 10154, pp. 1247–1256, 2018.
[2] S. T. Carmichael, “Rodent models of focal stroke: size, mechanism, and purpose,” NeuroRx, vol. 2, no. 3, pp. 396–409, 2005.
[3] J. D. Pandian, S. L. Gall, M. P. Kate et al., “Prevention of stroke: a global perspective,” Lancet, vol. 392, no. 10154, pp. 1269–1278, 2018.
[4] E. S. Donkor, “Stroke in the Century: A Snapshot of the Burden, Epidemiology, and Quality of Life,” Stroke Research and Treatment, vol. 2018, Article ID 3238165, 2018.
[5] G. A. Mensah, B. Norrving, and V. L. Feigin, “Global burden of stroke,” Circulation Research, vol. 120, pp. 439–448, 2017.
[6] J. Astrup, B. K. Siesjö, and L. Symon, “Thresholds in cerebral ischemia - the ischemic penumbra,” Stroke, vol. 12, no. 6, pp. 723–725, 1981.
[7] U. Dirnagl, C. Iadecola, and M. A. Moskowitz, “Pathobiology of ischaemic stroke: an integrated view,” Trends in Neurosciences, vol. 22, no. 9, pp. 391–397, 1999.
[8] P. Ramoscabrer, F. Campos, T. Sobrino, and J. Castillo, “Targeting the ischemic penumbra,” Stroke, vol. 42, 1_suppl_1, pp. 7–11, 2011.
[9] The GBD 2016 Lifetime Risk of Stroke Collaborators, “Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016,” The New England Journal of Medicine, vol. 379, no. 25, pp. 2429–2437, 2018.
[10] K. Strong, C. Mathers, and R. Bonita, “Preventing stroke: saving lives around the world,” Lancet Neurology, vol. 6, no. 2, pp. 182–187, 2007.
[11] W. Wang, B. Jiang, H. Sun et al., “Prevalence, incidence, and mortality of stroke in China results from a nationwide population-based survey of 480 687 adults,” Circulation, vol. 135, no. 8, pp. 759–771, 2017.
[12] J. M. Wardlaw and P. M. Bath, “Stroke research in 2018: extended time windows, refined benefit, and lifestyle prevention targets,” Lancet Neurology, vol. 18, no. 1, pp. 2-3, 2019.
[13] X. Huang, L. I. Li, R. X. Song, and H. M. Zhu, “Clinical efficacy of Zhuang medicine Zhixuetong enteric-coated capsule for apoplexy due to Qi deficiency and blood stasis,” Guangxi Medical Journal, vol. 39, no. 12, pp. 1769–1780, 2017.
[14] L. I. Cheng-Lin, Q. G. Wang, Z. D. Zhu, and D. She, “The protective effect of euonymus fortunei zhuang drugs on rabbit myocardial ischemia-reperfusion injury-induced cardiomyocyte apoptosis,” Liaoning Journal of Traditional Chinese Medicine, vol. 36, no. 11, pp. 1989–1991, 2009.

[15] X. Wan, H. C. Huang, X. P. Wang, Z. H. Hu, K. Y. Liu, and D. B. Huang, “Euonymus alatus and its monomers alleviate liver fibrosis both in mice and LX2 cells by blocking TβR1-Smad2/3 and TNF-α-NF-κB pathways,” American Journal of Translational Research, vol. 11, no. 1, pp. 106–119, 2019.

[16] W. Xie, X. Meng, Y. Zhai et al., “Panax Notoginseng saponins: a review of its mechanisms of antidepressant or anxiolytic effects and network analysis on phytochemistry and pharmacology,” Molecules, vol. 23, no. 4, p. 940, 2018.

[17] S. Sharma, A. Mandal, R. Kant, S. Jachak, and M. Jagzape, “Is cinnamon efficacious for glycaemic control in type-2 diabetes mellitus?,” The Journal of the Pakistan Medical Association, vol. 70, no. 11, pp. 2065–2069, 2020.

[18] S. Sadeghi, A. Davoodvandi, M. H. Pourhanifeh et al., “Anti-cancer effects of cinnamon: insights into its apoptosis effects,” European Journal of Medicinal Chemistry, vol. 178, pp. 131–140, 2019.

[19] X. Deng, S. Zhao, X. Liu et al., “Polygala tenuifolia: a source for anti-Alzheimer’s disease drugs,” Pharmaceutical Biology, vol. 58, no. 1, pp. 410–416, 2020.

[20] X. Chen, L. Wei, W. He et al., “Effects of zhuanzong drinking on endogenous neural stem cells in rats with cerebral infarction,” Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 16, no. 4, pp. 408–411, 2018.

[21] Y. Wang, Y. Wang, M. Li et al., “$^1$H NMR-based metabolomics exploring biomarkers in rat cerebrospinal fluid after cerebral ischemia/reperfusion,” Molecular BioSystems, vol. 9, no. 3, pp. 431–439, 2013.

[22] T. Zhang, W. Wang, J. Huang, X. Liu, H. Zhang, and N. Zhang, “Metabolomic investigation of regional brain tissue dysfunctions induced by global cerebral ischemia,” BMC Neuroscience, vol. 17, no. 1, p. 25, 2016.

[23] R. Habibey, M. Ajami, S. A. Ebrahimi, A. Hesami, S. Babakoohi, and H. Pazoki-Toroudi, “Nitric oxide and renal protection in morphine-dependent rats,” Free Radical Biology & Medicine, vol. 49, no. 6, pp. 1109–1118, 2010.

[24] Y. Yu, X. Zhang, B. Li et al., “Entropy-based divergent and convergent modular pattern reveals additive and synergistic anticerebral ischemia mechanisms,” Experimental Biology and Medicine: Journal of the Society for Experimental Biology and Medicine, vol. 241, no. 18, pp. 2063–2074, 2016.

[25] B. Bukowska, A. Gajek, and A. Marczak, “Two drugs are better than one. A short history of combined therapy of ovarian cancer,” Wspólczesna Onkologia, vol. 19, no. 5, pp. 350–353, 2015.

[26] Y. Y. Zhang, H. X. Li, Y. Y. Chen et al., “Convergent and divergent pathways decoding hierarchical additive mechanisms in treating cerebral ischemia-reperfusion injury,” CNS Neuroscience & Therapeutics, vol. 20, no. 3, pp. 253–263, 2014.

[27] V. Scheid, “Wellcome Trust-funded monographs and book chapters holism, Chinese medicine and systems ideologies: rewriting the past to imagine the future,” in The Edinburgh Companion to the Critical Medical Humanities, A. Whitehead, A. Woods, and S. Atkinson, Eds., Edinburgh University Press, © Edinburgh University Press, 2016.

[28] A. C. Rufer, “Drug discovery for enzymes,” Drug Discovery Today, vol. 26, no. 4, pp. 875–886, 2021.

[29] C. Ibáñez, C. Simó, D. K. Barupal et al., “A new metabolomic workflow for early detection of Alzheimer’s disease,” Journal of Chromatography A, vol. 1302, pp. 65–71, 2013.

[30] L. D. Roberts and R. E. Gerszten, “Toward new biomarkers of cardiometabolic diseases,” Cell Metabolism, vol. 18, no. 1, pp. 43–50, 2013.

[31] S. Tiziani, Y. Kang, R. Harjanto et al., “Metabolomics of the tumor microenvironment in pediatric acute lymphoblastic leukemia,” PLoS One, vol. 8, no. 12, article e82859, 2013.

[32] S. Tagore, N. Chowdhury, and R. K. De, “Analyzing methods for path mining with applications in metabolomics,” Gene, vol. 534, no. 2, pp. 125–138, 2014.

[33] C.-G. Liu, X.-L. Wang, X.-W. Du et al., “Metabolic profiling for identification of potential biomarkers in the protective effects of modified Sinisan against liver injury in dimethylnitrosamine treated rats,” Biological & Pharmaceutical Bulletin, vol. 36, no. 11, pp. 1700–1707, 2013.

[34] L. Wu, C. Chen, Y. Li et al., “UPLC-Q-TOF/MS-based serum metabolomics reveals the anti-ischemic stroke mechanism of nuciferine in MCAO rats,” ACS Omega, vol. 5, no. 51, pp. 33433–33444, 2020.

[35] J. S. Tian, S. B. Liu, X. Y. He et al., “Metabolomics studies on corticosterone-induced PC12 cells: a strategy for evaluating an in vitro depression model and revealing the metabolic regulation mechanism,” Neurotoxicology and Teratology, vol. 69, pp. 27–38, 2018.